Production (Stage)
Candel Therapeutics, Inc.
CADL
$5.03
-$0.13-2.52%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.92% | -45.44% | -63.49% | -55.34% | -39.87% |
| Total Depreciation and Amortization | 0.31% | 3.13% | 6.65% | 11.43% | 16.37% |
| Total Amortization of Deferred Charges | -30.21% | -16.41% | -4.10% | -1.52% | -0.90% |
| Total Other Non-Cash Items | 180.83% | 803.92% | 2,620.33% | 2,583.89% | 166.41% |
| Change in Net Operating Assets | -29.51% | 165.90% | 154.72% | 72.79% | 110.39% |
| Cash from Operations | 14.63% | 21.09% | 15.06% | 9.97% | 6.79% |
| Capital Expenditure | 96.32% | 96.50% | 91.25% | 79.57% | 74.21% |
| Sale of Property, Plant, and Equipment | -- | -- | -87.26% | -87.26% | -87.26% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 96.08% | 94.29% | 92.44% | 77.69% | 72.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -499.88% | -- | -- | -- | -- |
| Issuance of Common Stock | 25,061.41% | -- | 24,994.44% | 13,391.67% | 610.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 6,907.05% | 78,017.36% | 6,138.89% | 1,480.56% | -2,472.41% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 298.10% | 294.09% | 22.73% | 12.75% | 4.79% |